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Louise Bowman, MD,* Jorg Hager, PHD,† Mark Lathrop, PHD,† Rory Collins, FMEDSCI,*
on behalf of the MRC/BHF Heart Protection Study Collaborative Group
Oxford, United Kingdom; and Evry, France
Objectives The aim of this study was to test the effects of the KIF6 Trp719Arg polymorphism (rs20455) on vascular risk
and response to statin therapy in 18,348 participants from the Heart Protection Study.
Background There have been claims that noncarriers of the KIF6 719Arg variant receive little benefit from statin therapy.
Screening for this genetic variant is now being used to influence statin use.
Methods Participants received 40 mg simvastatin daily for 4 to 6 weeks before being randomly allocated 40 mg simvastatin
daily or placebo for 5 years. Major coronary event was pre-defined as coronary death or nonfatal myocardial infarc-
tion, and major vascular event was pre-defined as major coronary event plus revascularization or stroke.
Results The KIF6 genotype was not significantly associated, among placebo-allocated participants, with the risks of inci-
dent major vascular events, major coronary events, revascularizations, or strokes. Overall, 40 mg simvastatin
daily produced a 42% reduction in low-density lipoprotein cholesterol, which did not differ significantly by KIF6
719Arg carrier status (p  0.51). Proportional reductions in the risk of major vascular events with statin therapy
were similar (interaction p  0.70) and highly significant across KIF6 genotypes: 23% (95% confidence interval:
16% to 29%; p  5.3  1010) in carriers (Arg/Arg or Trp/Arg), and 24% (95% confidence interval: 17% to 31%;
p  4.6  109) in noncarriers (Trp/Trp). A similar lack of interaction was observed for major coronary events,
revascularizations, and strokes considered separately.
Conclusions Statin therapy significantly reduces the incidence of coronary and other major vascular events to a similar ex-
tent, irrespective of KIF6 genotype. Consequently, the use of KIF6 genotyping to guide statin therapy is not war-
ranted. (Heart Protection Study; ISRCTN48489393) (J Am Coll Cardiol 2011;57:2000–7) © 2011 by the
American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.02.015Statins are a widely prescribed, well-tolerated, and effective
approach to lowering blood concentrations of low-density
lipoprotein cholesterol (LDL-C) and the risk of vascular
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2011, accepted February 23, 2011.events. Standard statin regimens typically reduce LDL-C
concentrations by approximately 60 mg/dl (1.5 mmol/l) and
the risks of myocardial infarction (MI), revascularization,
and stroke by approximately one-third (1–3). Moreover,
large-scale randomized trials have demonstrated similar
proportional reductions in the risks of vascular events across
a wide variety of patients (1–3). Interest in personalized
medicine has resulted in efforts to identify genetic variants
that influence response to medications (4,5), including
statins (6–10). The effects of a few treatments have been
shown to vary by genotype (11), but it is important that any
claims of differential response are reliably tested to avoid
patients being wrongly denied effective therapy.
Some studies have suggested that carriers of the 719Arg
variant in KIF6 (which encodes kinesin-like protein 6)
might have as much as a 50% higher risk of vascular events
than noncarriers (12–17). In addition, 4 randomized trials
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May 17, 2011:2000–7 No Impact of KIF6 on Statin Responseinvolving a total of 1,521 incident vascular events have
generated the hypothesis that KIF6 genotype influences
ascular risk response to statin therapy (13,18,19). In
hose trials, noncarriers of the KIF6 719Arg variant seemed
not to benefit significantly from statin therapy, whereas risk
was reduced by between one-third and one-half among
carriers. A significant interaction between KIF6 genotype
nd the effect of statin therapy on vascular events was
eported in the PROVE-IT (Pravastatin or Atorvastatin
valuation and Infection Therapy) (adjusted p  0.02) and
OSCOPS (West of Scotland Coronary Prevention
tudy) studies (adjusted p  0.01) but not in the CARE
Cholesterol And Recurrent Events) (adjusted p  0.39) or
ROSPER (Prospective Study of Pravastatin in the Elderly
t Risk) studies (adjusted p  0.09). A recent update from
he CARE study, including nonwhites and all coronary
eaths in the outcome, still showed a nonsignificant (ad-
usted p  0.14) interaction (20).
The KIF6 gene is a member of the superfamily of motor
rotein kinesins that are involved in intracellular transport
21,22), but the biological plausibility for vascular risk or
tatin response is uncertain (23). The LDL-C reduction is
onsidered to be the main mechanism by which statins
educe vascular risk (2,3), but KIF6 genotype does not seem
o influence the LDL-C reduction produced by statin
herapy (18,19). Hence, it has been suggested that any
ifferential effect of statins on vascular risk produced by
IF6 genotype might be acting through other mechanisms
19). These claims of a differential response to statin therapy
ave prompted the marketing of KIF6 screening to assess
he suitability of statins for individual patients (24). For
xample, it is asserted that only 10 carriers with acute
oronary syndrome would require treatment with statin
herapy to avoid a single coronary event, compared with 125
oncarriers (19,25). Similarly, for patients with stable cor-
nary disease, it is claimed that the number needed to treat
o prevent 1 coronary event is only 16 for carriers compared
ith 83 for noncarriers (26).
The HPS (Heart Protection Study) of 40 mg simvastatin
aily versus placebo in over 20,000 randomized patients
nvolved considerably more incident vascular events (n 
,185) than the combination of all of the trials that
uggested that KIF6 genotype might influence the effects of
tatin therapy (1). Hence, it provides an opportunity to test
his hypothesis reliably.
ethods
tudy recruitment and follow-up. Details of the HPS
tudy have been reported previously (1,27). Between 1994
nd 1997, 20,536 men and women 40 to 80 years of age
ere recruited in the United Kingdom with ethics commit-
ee approval. Individuals were eligible provided they had
lood total cholesterol concentrations of at least 135 mg/dl
3.5 mmol/l) and a previous diagnosis of coronary, cerebro-
ascular, or other occlusive disease of noncoronary arteries,r diabetes mellitus, or (if men at
east 65 years of age) treated hy-
ertension. At the initial screening
isit, all participants provided writ-
en consent and began a “run-in”
hase involving 4 weeks of placebo
ollowed by 4 to 6 weeks of 40 mg
imvastatin daily, after which com-
liant and eligible individuals were
andomly allocated 40 mg simvastatin daily or placebo for a
ean of approximately 5 years. A nonfasting blood sample
as taken at screening (before starting statin therapy) and at
he end of run-in (while receiving 40 mg simvastatin daily).
The pre-specified outcomes of interest for assessing the
ffect of statin therapy in different subgroups were the first
ccurrence after randomization of incident major coronary
vents (defined as coronary death or nonfatal MI) and of
ncident major vascular events (defined as major coronary
vents, coronary or noncoronary revascularizations, or
trokes) (1). Further details of outcome ascertainment and
djudication are reported elsewhere (1,27).
enotyping assays. Extraction of deoxyribonucleic acid
rom stored white cells and genotyping was carried out at
he Centre National de Genotypage in Evry, France. Ge-
otypes of the KIF6 Trp719Arg polymorphism (rs20455)
ere available from the Illumina 610K-Quad panel for
,894 of 3,895 randomly selected white participants after
uality control exclusions based on discrepant sex, repeat
amples, poor success rate (95%), and nonwhite ethnic
rigin. A further 14,454 participants of self-reported white
thnicity were successfully genotyped for this variant with a
ustom I.PLEX panel run on samples from 14,481 individ-
als. Combined, KIF6 genotypes were available for 18,348
hite participants and were consistent with Hardy-
einberg equilibrium (p  0.09).
tatistical methods. Differences between baseline charac-
eristics were assessed by analysis of variance for continuous
ariables and by chi-square statistics for categorical variables
nd reported as 2-sided p values. Linear regression was used
o estimate the effects of KIF6 on LDL-C response to statin
y considering the difference in loge LDL-C levels at the
screening visit before starting statin and at the randomiza-
tion visit after 4 to 6 weeks on simvastatin in compliant
individuals who were then randomized. Cox proportional
hazard models were used to assess the association of KIF6
with the risk of incident disease and the effects of KIF6 on
the risk response to statin. The impact of KIF6 on outcomes
was tested primarily in a dominant genetic model (pdom)
omparing Arg/Arg plus Trp/Arg (719Arg “carriers”) versus
rp/Trp (“noncarriers”), as emphasized in the “hypothesis-
enerating” studies (13,18,19). The p values were also
btained for: the additive effect (padd) per 719Arg allele; and
enotypic effect (pgeno) comparing Arg/Arg versus Trp/Arg
versus Trp/Trp. Analyses were performed with SAS soft-
Abbreviations
and Acronyms
CI  confidence interval
LDL-C  low-density
lipoprotein cholesterol
MI  myocardial infarction
RR  risk ratioware (version 9.1, SAS Institute, Cary, North Carolina),
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No Impact of KIF6 on Statin Response May 17, 2011:2000–7and figures were generated with R software (version 2.10.1,
The R foundation for Statistical Computing, Vienna,
Austria).
Results
Characteristics. The frequency of the KIF6 719Arg allele
in the HPS study was 35% and 58% of the 18,348
genotyped participants had 719Arg “carrier” genotypes
(Trp/Arg or Arg/Arg), consistent with previous studies
(13,18,19). Selected characteristics at baseline did not differ
materially by KIF6 genotype (Table 1). Among simvastatin-
allocated participants, compliance with study tablets (80%
taken) ranged from 89% at the end of the first year of
follow-up to 80% at the end of the fifth year, yielding an
average during the study of 84% that did not differ by KIF6
genotype (p  0.99). Among those allocated placebo, 4% at
the end of the first year of follow-up but 33% at the end of
the fifth year were taking nonstudy statin therapy, yielding
an average of 17% that also did not differ by KIF6 genotype
p  0.89). The average difference between these groups in
he use of a statin was approximately 67% (84% minus 17%),
nd hence the “intention-to-treat” randomized comparisons
ssess the effects of approximately two-thirds of
imvastatin-allocated participants actually taking 40 mg
imvastatin daily.
ascular event risk by KIF6 genotype. The association of
IF6 with the risk of incident vascular events in the HPS
tudy was assessed in 9,181 placebo-allocated participants to
inimize any potential influence of statin therapy. During
ean follow-up of 5 years, 1,086 individuals had a major
oronary event, 1,069 had a revascularization procedure, and
47 had a stroke, yielding first major vascular events among
,335 participants. Figure 1 shows that there was no
ignificant effect of KIF6 genotype on the risk of major
ascular events, irrespective of the modeling approach used
pdom  0.54; padd  0.46; pgeno  0.76), or on any of the
Characteristics of Participants in the Heart Protection Study by KITable 1 Characteristics of Participants in the Heart Protection
Characteristic
KIF6 719 Genot
Arg/Arg Trp/Arg
Patients 2,359 8,291
Men 1,776 (75.3) 6,227 (75.1)
Age, yrs 63.9 (8.4) 64.0 (8.4)
Smoking
Never smoked 568 (24.1) 2,062 (24.9)
Ex-smoker 1,466 (62.1) 5,053 (61.0)
Current smoker 325 (13.8) 1,176 (14.2)
Diabetes 662 (28.1) 2,329 (28.1)
Hypertension 957 (40.6) 3,408 (41.1)
Body mass index, kg/m2 27.7 (4.4) 27.5 (4.3)
Prior disease
Prior myocardial infarction 945 (40.1) 3,505 (42.3)
Other coronary heart disease 606 (25.7) 1,974 (23.8)
No coronary heart disease 808 (34.3) 2,812 (33.9)Values are mean (SD) for continuous variables and n (%) for categorical variables. Dominant p value is te
p value is test of difference among Arg/Arg and Trp/Arg and Trp/Trp.omponents of this endpoint. Adjustment for additional
ovariates did not alter the results materially (data not
hown).
DL-C response to statin therapy by KIF6 genotype.
mong the 18,343 genotyped participants in the HPS study
ith LDL-C measurements available, mean (SE) plasma
DL-C concentration at the initial screening visit (“off-
tatin”) was 130.2 (0.23) mg/dl and did not differ by KIF6
enotype (Table 2). After compliance with 40 mg simva-
tatin daily (“on-statin”) during the pre-randomization
un-in phase, the mean plasma LDL-C concentration in
enotyped participants was 76.6 (0.18) mg/dl and again did
ot differ by KIF6 genotype. Mean LDL-C concentration
as reduced by 42.3% (95% confidence interval [CI]: 42.1%
o 42.5%), with no impact of KIF6 genotype on the LDL-C
esponse to simvastatin (pdom  0.51; padd  0.50; pgeno 
0.79). During mean post-randomization follow-up of 5
years, there was a 30% reduction in LDL-C among partic-
ipants who had been randomly allocated 40 mg simvastatin
daily compared with those allocated placebo (reflecting the
average difference of two-thirds in statin use), again with no
impact of KIF6 genotype (p  0.52).
Vascular event risk response to statin by KIF6 genotype.
mong the genotyped participants in the HPS study,
andom allocation to 40 mg simvastatin daily reduced the
elative risk of major vascular event by 23% (95% CI: 19% to
8%) (Fig. 2). The proportional reductions in the risk of
ajor vascular events were similar, irrespective of KIF6
enotype: 23% (95% CI: 16% to 29%) in 719Arg carriers
ersus 24% (95% CI: 17% to 31%) in noncarriers, with no
ignificant interaction (pdom  0.70; padd  0.40; pgeno 
.51). The previously reported “hypothesis-generating” ran-
omized trials focused chiefly on coronary events (variously
efined) (13,18,19), but the “hypothesis-testing” HPS study
gain found no evidence that the relative reduction in major
oronary events was affected by KIF6 genotype: 25% (95%
p719Arg (rs20455) Genotypey by KIF6 Trp719Arg (rs20455) Genotype
p Value
Trp/Trp Dominant p Value Genotypic p Value
7,698
5,775 (75.0) 0.85 0.97
64.3 (8.3) 0.04 0.09
1,842 (23.9) 0.23 0.36
4,748 (61.7) 0.52 0.47
1,108 (14.4) 0.57 0.75
2,166 (28.1) 0.94 0.99
3,194 (41.5) 0.49 0.71
27.7 (4.5) 0.04 0.03
3,203 (41.6) 0.81 0.15
1,812 (23.5) 0.28 0.09
2,683 (34.9) 0.22 0.46F6 TrStud
ypest of difference between 719Arg carriers (Arg/ArgArg/Trp) and noncarriers (Trp/Trp). Genotypic
2003JACC Vol. 57, No. 20, 2011 Hopewell et al.
May 17, 2011:2000–7 No Impact of KIF6 on Statin ResponseCI: 16% to 34%) in 719Arg carriers versus 28% (95% CI:
18% to 38%) in noncarriers. Likewise, there was no evidence
of any differential effect of simvastatin by KIF6 genotype on
the need for revascularization or risk of stroke considered
separately (after allowance for the number of comparisons).
Figure 1 Association of KIF6 Genotype With Major Vascular Ev
Hazard ratios for each genotype are indicated by squares (size inversely proportion
Pre-Randomization LDL-C and LDL-C Response to Simvastatin in thby KIF6 Trp719Arg (rs20455) GenotypeTable 2 Pre-Randomiz tion LDL-C and LDL-C Response to Simvby KIF6 Trp719Arg (rs20455) Genotype
KIF6 Genotype n
LDL-C (mg/d
Mean (SE)
Off-Statin
719 Trp/Trp 7,696 130.2 (0.36)
719 Trp/Arg 8,290 130.2 (0.34)
719 Arg/Arg 2,357 130.5 (0.64)
719 Arg carriers 10,647 130.2 (0.30)
Overall 18,343 130.2 (0.23)
Off-statin measurements are taken at screening; on-statin measurements are taken after 4 to 6 w
2age, age , sex, and age  sex interaction.
LDL-C  low-density lipoprotein cholesterol.Adjustment for additional covariates did not alter the results
materially (data not shown).
Comparisons with previous trials of statin response by
KIF6 genotype. Figure 3 compares the observed effects
of statin therapy on vascular events by KIF6 genotype in
Among Placebo-Allocated Participants
ariance) with horizontal lines indicating 95% confidence intervals (CIs).
rt Protection Studyin in th Heart Protection Study
LDL-C Reduction
% (95% CI)
p Value for Interaction
(Statin  Genotype)*-Statin
.6 (0.28) 42.3 (42.0–42.6)
.6 (0.27) 42.4 (42.1–42.7) 0.51 (dominant)
.8 (0.51) 42.4 (41.8–42.9) 0.50 (additive)
.6 (0.24) 42.4 (42.1–42.6) 0.79 (genotypic)
.6 (0.18) 42.3 (42.1–42.5)
pre-randomization treatment with 40 mg simvastatin daily. *The p value from model adjusted forents
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No Impact of KIF6 on Statin Response May 17, 2011:2000–7the “hypothesis-generating” trials (13,18,19) and in the
present analysis of “hypothesis-testing” HPS (which
involved approximately 3 times as many vascular events as
in all of the previous trials combined). In the “hypothesis-
generating” trials, the statin benefits seemed to be greater
in KIF6 carriers (weighted carrier to noncarrier ratio of
Rs: 0.64; 95% CI: 0.51 to 0.79), but this trend chiefly
eflects differences between the carrier versus noncarrier
ascular event rates in the control arm rather than
ifferences among participants allocated statin. By con-
rast, in the HPS study, vascular event rates were very
imilar in carriers and noncarriers, both among those
llocated placebo (25.3% and 25.7%, respectively) and
mong those allocated simvastatin (20.2% and 20.1%,
espectively). Consequently, the relative reduction in risk
ith allocation to simvastatin in the HPS study was
imilar, irrespective of genotype (carrier to noncarrier
atio of RRs: 1.02) and, given the large numbers of events
n which this test of the hypothesis is based, was not
onsistent with there being much difference in the size of
Figure 2 Effects of Simvastatin on Major Vascular Events by K
Conventions as for Figure 1. Hazard ratios and 95% confidence intervals (CIs) forhe risk reduction (95% CI: 0.91 to 1.16). discussion
he present large-scale test using the HPS randomized trial
oes not confirm the hypothesis that KIF6 genotype is
mportantly relevant either to the overall risk of vascular
vents or to the effects of statin therapy on vascular risk.
The most extreme associations of KIF6 carrier status with
isk of incident vascular events were reported in the placebo
roups of the CARE (RR: 1.57; 95% CI: 1.10 to 2.25) and
OSCOPS (RR: 1.59; 95% CI: 1.18 to 2.14) studies based
n 142 and 276 coronary disease cases, respectively (13).
hese initial “hypothesis-generating” analyses involved test-
ng 35 genetic polymorphisms for risk associations and
lacing data-dependent emphasis on the most extreme risk
ssociation in further analyses, which was for KIF6. By
ontrast, no significant associations were observed in the
lacebo group of the PROSPER study overall (adjusted RR:
.06; 95% CI: 0.86 to 1.30) (18) based on 379 coronary
isease cases or in the HPS study (RR: 0.97; 95% CI: 0.90
o 1.06) based on 2,335 coronary or other vascular disease
ases. Studies among people with pre-existing vascular
enotype
ticipants combined are indicated by diamonds.IF6 G
all parisease (such as in these trials) might not be optimal for
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May 17, 2011:2000–7 No Impact of KIF6 on Statin Responsedetecting genetic associations with vascular risk, because the
underlying effect might be attenuated. Moderate associa-
tions of KIF6 genotype with the risk of vascular events in
eople of white ethnic origin have been reported by some
opulation-based observational studies (12,16,17). How-
ver, the Ottawa Heart Study and a recent meta-analysis of
9 case-control studies involving 17,000 coronary disease
ases found no association between KIF6 carrier status and
he risk of coronary disease (28,29). Furthermore, large scale
enome-wide association studies involving several thousand
isease cases have also failed to report an association of
IF6 with major coronary events (30–34). Nor have asso-
iations of KIF6 with stroke been reliably demonstrated
15,35,36).
The lipid-lowering effects of statin therapy do not seem
o be materially influenced by KIF6 genotype. For example,
t was not previously found to be associated with pre-
reatment cholesterol concentrations or with lipid response
o statin therapy among approximately 20,000 and 6,000
ndividuals, respectively, in genome-wide scans followed by
eplication studies (37,38). The effects of KIF6 genotype on
holesterol concentrations have not been reported for the
ARE and WOSCOPS placebo-controlled trials of 40 mg
ravastatin daily (13,20). Among 5,752 patients in the
ROSPER study, however, no significant differences were
bserved between KIF6 carriers and noncarriers in baseline
holesterol concentrations or in the LDL-C reductions
Figure 3 Effects of Statin Therapy on Vascular Events by KIF6
“Hypothesis-Generating” and “Hypothesis-Testing”
Carrier versus noncarrier ratios of risk ratios for the effects of statin therapy in ea
lines indicating 95% confidence intervals (CIs). For comparability, all risk ratios are
from the available data). Treatment comparisons: 40 mg pravastatin daily versus
Coronary Prevention Study), and PROSPER (Prospective Study of Pravastatin in the
PROVE-IT (Pravastatin or Atorvastatin Evaluation and Infection Therapy) study; and
event outcomes: fatal or nonfatal myocardial infarction (MI) in the CARE study; an
PER studies; death from any cause, nonfatal MI, unstable angina, coronary revasc
noncoronary revascularization, or stroke in the HPS study. Data for PROSPER areroduced by 40 mg pravastatin daily (18). Similarly, among s,778 patients in the PROVE-IT study, KIF6 genotype did
ot seem to have any material effect on cholesterol concen-
rations (19). These findings are consistent with the results
mong 18,343 genotyped participants in the HPS study,
here actual use of 40 mg simvastatin daily for 4 to 6 weeks
roduced a 42% LDL-C reduction, while two-thirds com-
liance to the random allocation of 40 mg simvastatin daily
ersus placebo for 5 years produced an average 30% LDL-C
eduction, irrespective of KIF6 genotype. It has been sug-
ested that the apparent lack of effect of statin therapy on
ascular events in some trials among KIF6 noncarriers,
espite LDL-C being lowered to a similar extent as among
arriers, provides evidence that the benefits of statin therapy
re independent of LDL-C lowering effects (i.e., pleiotropic
echanisms) (19). Consequently, if a lack of effect of statin
herapy on vascular events among KIF6 719Arg noncarriers
ad been reliably demonstrated, it would have had impor-
ant biological as well as therapeutic implications.
Large-scale meta-analyses of randomized trials have
hown that statin therapy reduces not only the risk of
oronary death and nonfatal MI but also the need for
evascularization procedures and the risk of ischemic stroke
2,3). Previously reported trials of the effects of KIF6
enotype on statin response have assessed different vascular
utcomes: the CARE study used the composite of fatal or
onfatal MI (13) (expanded subsequently to include all
oronary deaths [20]); the WOSCOPS and PROSPER
type in the
l are indicated by squares (size inversely proportional to variance) with horizontal
d on unadjusted analyses (estimated, if not cited in the related publications,
o in the CARE (Cholesterol And Recurrent Events), WOSCOPS (West of Scotland
ly at Risk) studies; 80 mg atorvastatin daily versus 40 mg pravastatin daily in the
simvastatin daily versus placebo in the HPS (Heart Protection Study). Vascular
ary death, nonfatal MI, or coronary revascularization in the WOSCOPS and PROS-
tion, or stroke in the PROVE-IT trial; and coronary death, nonfatal MI, coronary or
ients with prior vascular disease.Geno
Trials
ch tria
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No Impact of KIF6 on Statin Response May 17, 2011:2000–7MI, or coronary revascularization (13,18); and the PROVE-IT
study used the composite of death from any cause or major
cardiovascular event (which included MI, unstable angina,
coronary revascularization, and stroke) (19). The extreme
statistical significance of the reduction in any major vascular
event (p  2.3  1017) in the HPS study and the large
number of events (n  4,185) on which it was based (1)
allowed particularly reliable assessment of the effects of
statin treatment in different circumstances. Consequently,
this “hypothesis-testing” analysis in the HPS study has been
able to demonstrate not only that statin therapy produces
similar proportional reductions in the risk of major vascular
events among KIF6 carriers and noncarriers (23% and 24%,
respectively) but also that these benefits are highly signifi-
cant both among carriers (95% CI: 16% to 29%; p  5.3 
1010) and, by contrast with the “hypothesis-generating”
rials, among noncarriers (95% CI: 17% to 31%; p  4.6 
09) (Fig. 2). Moreover, the findings were similar in the
PS study when such analyses were conducted separately
or major coronary events or for other major vascular events.
he CARE, WOSCOPS, and PROSPER studies tested
ravastatin (which is not now widely used), and the
ROVE-IT study compared atorvastatin versus pravastatin,
hereas the HPS study tested simvastatin. One cannot
xclude the possibility, although unlikely, that the type of
tatin might be important for KIF6 interaction. But, in the
arge-scale meta-analyses of randomized trials of statin
herapy, the relative reductions in major vascular events
ere proportional to the absolute reductions in LDL-C
irrespective of the statin used) and were similar in all of the
ubgroups considered (2,3). Therefore, it seems most prob-
ble that the apparent KIF6 interaction in the “hypothesis-
generating” trials is due chiefly (if not entirely) to selective
emphasis on data-derived findings based on relatively small
numbers of events.
During the HPS study, an average of approximately one-
sixth of participants allocated 40 mg simvastatin daily stopped
taking statin therapy, and approximately one-sixth of placebo-
allocated participants started taking a statin. Therefore, the
observed average difference in LDL-C of approximately 40
mg/dl (1 mmol/l) between simvastatin-allocated and placebo-
allocated participants represents only approximately two-thirds
of the LDL-C difference produced by actual use of 40 mg
simvastatin daily. Similarly, the reduction of approximately
one-quarter in major vascular events in the intention-to-treat
comparison is likely to represent only approximately two-thirds
of the risk reduction produced by full compliance with this
statin regimen. Hence, actual use of 40 mg simvastatin daily
would be expected to lower LDL-C by approximately 60
mg/dl (1.5 mmol/l) in this population and reduce the rates of
major vascular events by approximately one-third, irrespective
of KIF6 genotype. Such noncompliance could not, however,
lausibly result in a positive bias whereby benefit would be
alsely observed among noncarriers despite a real lack of
enefit.onclusions
he KIF6 719Arg noncarrier genotype is relatively common
approximately 40% of all whites are noncarriers), and
ence, concluding falsely that noncarriers will not benefit
rom statin therapy might lead to a very large number of
nnecessary vascular events and deaths. The results of the
PS study demonstrate unequivocally that statin therapy
roduces substantial beneficial effects on coronary and other
ajor vascular events, irrespective of whether an individual
s a KIF6 719Arg carrier or noncarrier. Consequently,
esting for KIF6 genetic variants is not warranted for
uiding the use of statin therapy (or other interventions
imed at lowering cardiovascular risk).
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